Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2008 Jan 26;336(7637):195-8.
doi: 10.1136/bmj.39430.529549.BE. Epub 2008 Jan 17.

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

George Krasopoulos  1 , Stephanie J Brister, W Scott Beattie, Michael R Buchanan
Affiliations
Meta-Analysis

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

George Krasopoulos et al. BMJ. .

Abstract

Objective: To determine if there is a relation between aspirin "resistance" and clinical outcomes in patients with cardiovascular disease.

Design: Systematic review and meta-analysis.

Data source: Electronic literature search without language restrictions of four databases and hand search of bibliographies for other relevant articles.

Review methods: Inclusion criteria included a test for platelet responsiveness and clinical outcomes. Aspirin resistance was assessed, using a variety of platelet function assays.

Results: 20 studies totalling 2930 patients with cardiovascular disease were identified. Most studies used aspirin regimens, ranging from 75-325 mg daily, and six studies included adjunct antiplatelet therapy. Compliance was confirmed directly in 14 studies and by telephone or interviews in three. Information was insufficient to assess compliance in three studies. Overall, 810 patients (28%) were classified as aspirin resistant. A cardiovascular related event occurred in 41% of patients (odds ratio 3.85, 95% confidence interval 3.08 to 4.80), death in 5.7% (5.99, 2.28 to 15.72), and an acute coronary syndrome in 39.4% (4.06, 2.96 to 5.56). Aspirin resistant patients did not benefit from other antiplatelet treatment.

Conclusion: Patients who are resistant to aspirin are at a greater risk of clinically important cardiovascular morbidity long term than patients who are sensitive to aspirin.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

None
Fig 1 Flow of papers through review process
None
Fig 2 Risk of any cardiovascular event in aspirin resistant patients
None
Fig 3 Risks of any cardiovascular event in aspirin resistant and aspirin sensitive patients treated with aspirin alone, and aspirin and clopidogrel (with or without an inhibitor of platelet glycoprotein IIb/IIIa)
None
Fig 4 Dose related effect of aspirin on cardiovascular outcome
None
Fig 5 Funnel plot for detection of possible publication bias
See this image and copyright information in PMC

Comment in

References

    1. Aspirin Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106. - PMC - PubMed
    1. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-83. - PubMed
    1. Lee PY, Chen WH, Ng W, Cheng X, Kwok JY, Tse HF, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005;118:723-7. - PubMed
    1. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995;11:221-7. - PubMed
    1. Quinn MJ, Aronow HD, Califf RM, Bhatt DL, Sapp S, Kleiman NS, et al. Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol 2004;43:972-8. - PubMed